Autopsy report · NCT05221320

Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

“Lack of Enrollment for Remaining Open Baskets”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 2 years 2 months before it stopped.
• 47 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

BioMed Valley Discoveries, Inc

Sponsor type

Industry

Conditions

Tumor, Solid; Gastrointestinal Cancer

Interventions

Ulixertinib; Hydroxychloroquine

Participants

47

Sites

9

Countries

United States

Trials that died the same way

• Effect of Adjuvant Hyperbaric Oxygen Therapy on Bells Palsy Outcome
  “lack of enrollment” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.